BI & Lilly Empagliflozin a Winner Targeting Adults with HFpEF — Canadian PI Awaits Approval

A cardiologist from Canada’s St. Boniface Hospital participated in a clinical trial involving a drug that at first was developed to address diabetes however after substantial clinical investigation it appeared that the SGLT inhibitor called Empagliflozin could contribute to helping reduce heart failure in patients leading to a healthier, better quality of life. That’s the takeaway of Dr. Shelley Zieroth, a principal investigator in The Emperor-Preserved Trial which investigated Empagliflozin. And that’s what the data shows as the industry sponsors reported on the results of the pivotal Phase 3 Emperor-Preserved trial. Sponsored by Germany’s Boehringer Ingelheim, the world’s biggest privately held pharmaceutical company, and Indianapolis-based Eli Lilly next comes the move to submit a market global regulatory submission planned for 2021.

Recently showcased in the local Winnipeg press, Dr. Zieroth shared that the study investigated the drug’s safety and efficacy in heart failure patients with preserved injection fraction a type of heart failure, a condition where the heart stops working as well due to stiffness. The Winnipeg clinical investigator and physician...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee